Toxicology issues related to covid -19
The role of toxicology in the COVID–19 pandemic known as Coronavirus disease 2019 (COVID–19) and previous pandemics have been viewed almost exclusively as virology problems, with toxicology problems mostly being ignored. This perspective is not supported by the evolution of COVID–19, where the impact of real-life exposures to multiple toxic stressors degrading the immune system is followed by the SARS–COV–2 virus exploiting the dysfunctional immune system to trigger a chain of events ultimately leading to COVID–19. This immune system degradation from multiple toxic stressors (chemical, physical, biological, psychosocial stressors) means that attribution of serious consequences from COVID–19 should be made to the virus-toxic stressors nexu
- Anti-biotics used in covid -19
- Immune system dysfunction in pandemics
- Immune system toxicology
- Vaccine toxicology
- Treatments for COVID–19
- Medical Toxicology and COVID-19
- Computational tools and In silico models
Related Conference of Toxicology issues related to covid -19
7th International Conference on Clinical Pharmacology and Toxicology
9th International Conference on Global Toxicology and Risk Assessment
Toxicology issues related to covid -19 Conference Speakers
Recommended Sessions
- Advances in Pharmacology
- Analytical Toxicology
- Biochemical and Molecular Toxicology
- Biomedical Toxicology
- Clinical Pharmacology
- Clinical Toxicology
- Drug discovery and Development
- Excitotoxicity
- Food Safety and Environmental Toxicity
- Forensic Toxicology
- Genetic Toxicology
- Inhalation Toxicology
- Medical Toxicology
- Neuro Toxicology
- Organ Toxicology
- Paediatric Toxicology
- Pharmacological Testing
- Pharmacology
- Pharmacy and Pharmaceutical Technology
- Recent Advances in Pharmacology and Toxicology
- Toxicity Testing
- Toxicology
- Toxicology and Risk Assessment
- Toxicology Applications
- Toxicology issues related to covid -19
- Toxicology Methods and Mechanisms
Related Journals
Are you interested in
- Adverse Drug Reactions and Pharmacovigilance - clinical pharmacology 2025 (Switzerland)
- Cardiovascular Pharmacology - clinical pharmacology 2025 (Switzerland)
- Clinical Toxicology of Drugs of Abuse - clinical pharmacology 2025 (Switzerland)
- Clinical Trials and Regulatory Affairs - clinical pharmacology 2025 (Switzerland)
- Drug Interactions and Polypharmacy - clinical pharmacology 2025 (Switzerland)
- Emerging Trends in Clinical Pharmacology - clinical pharmacology 2025 (Switzerland)
- Environmental and Occupational Toxicology - clinical pharmacology 2025 (Switzerland)
- Future Directions in Clinical Pharmacology and Toxicology - clinical pharmacology 2025 (Switzerland)
- Innovations in Drug Development and Therapeutics - clinical pharmacology 2025 (Switzerland)
- Natural Products and Toxicology - clinical pharmacology 2025 (Switzerland)
- Neuropharmacology and Toxicology - clinical pharmacology 2025 (Switzerland)
- Pediatric and Geriatric Pharmacology - clinical pharmacology 2025 (Switzerland)
- Pharmacogenomics and Personalized Medicine - clinical pharmacology 2025 (Switzerland)
- Pharmacokinetics and Pharmacodynamics - clinical pharmacology 2025 (Switzerland)
- Toxicology and Risk Assessment - clinical pharmacology 2025 (Switzerland)

